Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Growth in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,450,000 shares, an increase of 17.9% from the November 15th total of 1,230,000 shares. Based on an average daily trading volume, of 487,900 shares, the short-interest ratio is currently 3.0 days. Approximately 1.7% of the shares of the company are short sold.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CMPX. Renaissance Technologies LLC increased its holdings in shares of Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after buying an additional 12,315 shares during the period. Vanguard Group Inc. increased its stake in shares of Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after buying an additional 71,008 shares during the period. Panagora Asset Management Inc. bought a new stake in shares of Compass Therapeutics during the second quarter worth $68,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Compass Therapeutics during the second quarter valued at $41,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on CMPX shares. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, November 11th. Finally, Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $6.75.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock remained flat at $1.46 during mid-day trading on Monday. 173,642 shares of the company were exchanged, compared to its average volume of 438,574. The company has a market capitalization of $200.88 million, a P/E ratio of -4.07 and a beta of 0.89. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The company has a fifty day simple moving average of $1.68 and a 200-day simple moving average of $1.41.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, equities research analysts expect that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.